Down-regulation of amyloid-β through AMPK activation by inhibitors of GSK-3β in SH-SY5Y and SH-SY5Y-AβPP695 cells

Journal of Alzheimer's Disease

Volumn 29, Issue 1, 2012, Pages 89-98

  Cai, Zhiyou ^a,b   Li, Benyi ^b   Li, Keshen ^a   Zhao, Bin ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

5 AMP activated protein kinase; amyloid protein; glycogen synthase kinase 3

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LITHIUM CHLORIDE; TDZD8; THIADIAZOLE DERIVATIVE; THIADIAZOLIDINONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84863247751     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-111649     Document Type: Article

References (58)

1. Buoso E, Lanni C, Schettini G, Govoni S, Racchi M (2010) beta-Amyloid precursor protein metabolism: Focus on the functions and degradation of its intracellular domain. Pharmacol Res 62, 308-317.
2. Mancuso M, Orsucci D, LoGerfo A, Calsolaro V, Siciliano G (2010) Clinical features and pathogenesis of Alzheimer's disease: Involvement of mitochondria and mitochondrial DNA. Adv Exp Med Biol 685, 34-44.
3. Price DL, Sisodia SS, Gandy SE (1995) Amyloid beta amyloidosis in Alzheimer's disease. Curr Opin Neurol 8, 268-274.
4. Kurt MA, Davies DC, Kidd M (1997) Paired helical filament morphology varies with intracellular location in Alzheimer's disease brain. Neurosci Lett 239, 41-44. (Pubitemid 28055845)
5. Sisodia SS, Price DL (1995) Role of the beta-amyloid protein in Alzheimer's disease. FASEB J 9, 366-370.
6. Finder VH (2010) Alzheimer's disease: A general introduction and pathomechanism. J Alzheimers Dis 22(Suppl 3), 5-19.
7. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, CitronM(1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
8. Venugopal C, Demos CM, Rao KS, Pappolla MA, Sambamurti K (2008) Beta-secretase: Structure, function, and evolution. CNS Neurol Disord Drug Targets 7, 278-294.
9. Eldar-Finkelman H, Licht-Murava A, Pietrokovski S, Eisenstein M (2010) Substrate competitive GSK-3 inhibitors - strategy and implications. Biochim Biophys Acta 1804, 598-603.
10. Doble BW, Woodgett JR (2003) GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci 116, 1175-1186. (Pubitemid 36410657)
11. Forde JE, Dale TC (2007) Glycogen synthase kinase 3: A key regulator of cellular fate. Cell Mol Life Sci 64, 1930-1944. (Pubitemid 47094432)
12. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR (2007) Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell 12, 957-971. (Pubitemid 46805920)
13. Takashima A (2006) GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 9, 309-317.
14. Ryder J, Su Y, Liu F, Li B, Zhou Y, Ni B (2003) Divergent roles of GSK3 and CDK5 in APP processing. Biochem Biophys Res Commun 312, 922-929. (Pubitemid 37490904)
15. Avila J, Hernandez F (2007) GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother 7, 1527-1533. (Pubitemid 350106832)
16. Won JS, Im YB, Kim J, Singh AK, Singh I (2010) Involvement of AMP-activated protein kinase (AMPK) in neuronal amyloidogenesis. Biochem Biophys Res Commun 399, 487-491.
17. Wang Y, Li X, Guo Y, Chan L, Guan X (2010) alpha-Lipoic acid increases energy expenditure by enhancing adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling in the skeletal muscle of aged mice. Metabolism 59, 967-976.
18. Webster I, Friedrich SO, Lochner A, Huisamen B (2010) AMP kinase activation and glut4 translocation in isolated cardiomyocytes. Cardiovasc J Afr 21, 72-78.
19. Littler DR, Walker JR, Davis T, Wybenga-Groot LE, Finerty PJ Jr, Newman E, Mackenzie F, Dhe-Paganon S (2010) A conserved mechanism of autoinhibition for the AMPK kinase domain: ATP-binding site and catalytic loop refolding as a means of regulation. Acta Crystallogr Sect F Struct Biol Cryst Commun 66, 143-151.
20. Kwon KJ, Kim HJ, Shin CY, Han SH (2010) Melatonin potentiates the neuroprotective properties of resveratrol against beta-amyloid-induced neurodegeneration by modulating AMP-activated protein kinase pathways. J Clin Neurol 6, 127-137.
21. Tanii H, Ankarcrona M, Flood F, Nilsberth C, Mehta ND, Perez-Tur J, Winblad B, Benedikz E, Cowburn RF (2000) Alzheimer's disease presenilin-1 exon 9 deletion and L250S mutations sensitize SH-SY5Y neuroblastoma cells to hyperosmotic stress-induced apoptosis. Neuroscience 95, 593-601.
22. Lee J, Kim CH, Kim DG, Ahn YS (2009) Zinc inhibits amyloid beta production from Alzheimer's amyloid precursor protein in SH-SY5Y cells. Korean J Physiol Pharmacol 13, 195-200.
23. Hooff GP, Peters I, Wood WG, Muller WE, Eckert GP (2010) Modulation of cholesterol, farnesylpyrophosphate, and geranylgeranylpyrophosphate in neuroblastoma SH-SY5Y-APP695 cells: Impact on amyloid beta-protein production. Mol Neurobiol 41, 341-350.
24. Wirths O, Thelen KM, Lutjohann D, Falkai P, Bayer TA (2007) Altered cholesterol metabolism in APP695-transfected neuroblastoma cells. Brain Res 1152, 209-214. (Pubitemid 46802505)
25. Ohgami T, Kitamoto T, Tateishi J (1993) The rat central nervous system expresses Alzheimer's amyloid precursor protein APP695, but not APP677 (L-APP form). J Neurochem 61, 1553-1556. (Pubitemid 23285120)
26. Jäger S, Leuchtenberger S, Martin A, Czirr E, Wesselowski J, Dieckmann M, Waldron E, Korth C, Koo EH, Heneka M, Weggen S, Pietrzik CU (2009) alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Abeta generation. J Neurochem 111, 1369-1382.
27. Yang J, Takahashi Y, Cheng E, Liu J, Terranova PF, Zhao B, Thrasher JB, Wang HG, Li B (2010) GSK-3beta promotes cell survival by modulating Bif-1-dependent autophagy and cell death. J Cell Sci 123, 861-870.
28. Zhiyou C, Yong Y, Shanquan S, Jun Z, Liangguo H, Ling Y, Jieying L (2009) Upregulation of BACE1 and betaamyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer's disease. Neurochem Res 34, 1226-1235.
29. Cai ZY,YanY, Chen R (2010) Minocycline reduces astrocytic reactivation and neuroinflammation in the hippocampus of a vascular cognitive impairment rat model. Neurosci Bull 26, 28-36.
30. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, Lobo J, Ferruzzi MG, Davies P, Marambaud P (2010) AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 285, 9100-9113.
31. Tschape JA, Hammerschmied C, Muhlig-Versen M, Athenstaedt K, Daum G, Kretzschmar D (2002) The neurodegeneration mutant lochrig interferes with cholesterol homeostasis and Appl processing. EMBO J 2, 6367-6376. (Pubitemid 35448415)
32. Ferreira IL, Resende R, Ferreiro E, Rego AC, Pereira CF (2010) Multiple defects in energy metabolism in Alzheimer's disease. Curr Drug Targets 11, 1193-1206.
33. Hirono N, Mori E, Ishii K, Ikejiri Y, Imamura T, Shimomura T, Hashimoto M, Yamashita H, SasakiM(1998) Frontal lobe hypometabolism and depression in Alzheimer's disease. Neurology 50, 380-383. (Pubitemid 28119774)
34. Yoon SY, Choi JE, Huh JW, Hwang O, Nam Hong H, Kim D (2005) Inactivation of GSK-3beta in okadaic acid-induced neurodegeneration: Relevance to Alzheimer's disease. Neuroreport 16, 223-227. (Pubitemid 40364580)
35. Gambassi G, Bernabei R (1998) Insulin, diabetes mellitus, Alzheimer's disease, and apolipoprotein E. Neurology 51, 925-926. (Pubitemid 28449310)
36. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7, 63-80. (Pubitemid 40387185)
37. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A (2009) Glycogen synthase kinase 3: More than a namesake. Br J Pharmacol 156, 885-898.
38. Messier C, Gagnon M (1996) Glucose regulation and cognitive functions: Relation to Alzheimer's disease and diabetes. Behav Brain Res 75, 1-11. (Pubitemid 26076738)
39. Merlini M, Meyer EP, Ulmann-Schuler A, Nitsch RM (2011) Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAbeta mice. Acta Neuropathol 122, 293-311.
40. Yan FL, Zheng Y, Zhao FD (2008) Effects of ginkgo biloba extract EGb761 on expression ofRAGEand LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia. Acta Neuropathol 116, 529-535.
41. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9, 13-33.
42. Ferreira IL, Resende R, Ferreiro E, Rego AC, Pereira CF (2010) Multiple defects in energy metabolism in Alzheimer's disease. Curr Drug Targets 11, 1193-1206.
43. Newcomer JW, Craft S, Fucetola R, Moldin SO, Selke G, Paras L, Miller R (1999) Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr Bull 25, 321-335. (Pubitemid 29272508)
44. Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuk V, Jin J, Harper JW, Ericsson J (2005) Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab 1, 379-391. (Pubitemid 43960622)
45. Casarejos MJ, Solano RM, Gomez A, Perucho J, de Yebenes JG, Mena MA (2011) The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells. Neurochem Int 58, 512-520.
46. Marks N, Berg MJ (2010) BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis. Neurochem Res 35, 181-210.
47. Benjannet S, Elagoz A, Wickham L, Mamarbachi M, Munzer JS, Basak A, Lazure C, Cromlish JA, Sisodia S, Checler F, Chrétien M, Seidah NG (2001) Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J Biol Chem 276, 10879-10887. (Pubitemid 38089265)
48. Muyllaert D, Kremer A, Jaworski T, Borghgraef P, Devijver H, Croes S, Dewachter I, Van Leuven F (2008) Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology? Genes Brain Behav 7, 57-66.
49. Aplin AE, Jacobsen JS, Anderton BH, Gallo JM (1997) Effect of increased glycogen synthase kinase-3 activity upon the maturation of the amyloid precursor protein in transfected cells. Neuroreport 8, 639-643. (Pubitemid 27128208)
50. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martinez A, Perez-Castillo A (2005) Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator- activated receptor gamma activation. J Biol Chem 280, 21453-21462. (Pubitemid 40805710)
51. Martinez A, Alonso M, Castro A, Perez C, Moreno FJ (2002) First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 45, 1292-1299. (Pubitemid 34263565)
52. Serenó L, Coma M, Rodríguez M, Sánchez-Ferrer P, Sánchez MB, Gich I, Agulló JM, Pérez M, Avila J, Guardia-Laguarta C, Clarimón J, Lleó A, Gómez-Isla T (2009) A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 35, 359-367.
53. Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, Frölich L, Schröder J, Schönknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Möller HJ, Kurz A, Basun H (2009) Lithium trial in Alzheimer's disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70, 922-931.
54. Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S (2008) A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry 23, 704-711.
55. Hu S, Begum AN, Jones MR, Oh MS, Beech WK, Beech BH, Yang F, Chen P, Ubeda OJ, Kim PC, Davies P, Ma Q, Cole GM, Frautschy SA (2009) GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 33, 193-206.
56. Panza F, Solfrizzi V, Frisardi V, Imbimbo BP, Capurso C, D'Introno A, Colacicco AM, Seripa D, Vendemiale G, Capurso A, Pilotto A (2009) Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: Drugs targeting beta-amyloid and tau protein. Aging Clin Exp Res 21, 386-406.
57. Ohsaka Y, Nishino H, Nomura Y (2010) Induction of phospho-Thr-172 AMPK in 3T3-L1 adipocytes exposed to cold or treated with anisomycin, mithramycin A, and ionic compounds. Cryo Letters 31, 218-229.
58. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N (2005) Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280, 32081-32089. (Pubitemid 41361813)